This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Coherus BioSciences, a clinical-stage biologics platform company focused on the emerging biosimilars market, raised $85 million by offering 6.3 million shares at $13.50, the midpoint of the range of $12 to $15. Insiders planned to buy $35 million on the IPO....read more
12 US IPOs are expected to raise $1.7 billion this week. Following three weeks with 5 or fewer initial public offerings, the IPO calendar has quickly built up thanks to...read more
Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, announced terms for its IPO on Friday. The Redwood City, CA-based company plans to raise $85 million by offering 6.3 million shares at a price...read more
US IPO Weekly Recap: 8 companies go public with strong returns as 5 delay IPOs
This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Coherus BioSciences prices IPO at $13.50 midpoint
Coherus BioSciences, a clinical-stage biologics platform company focused on the emerging biosimilars market, raised $85 million by offering 6.3 million shares at $13.50, the midpoint of the range of $12 to $15. Insiders planned to buy $35 million on the IPO....read more
Week Ahead: 12 US IPOs planned for the week of November 3 as the IPO market reignites
12 US IPOs are expected to raise $1.7 billion this week. Following three weeks with 5 or fewer initial public offerings, the IPO calendar has quickly built up thanks to...read more
Enbrel biosimilar biotech Coherus BioSciences sets terms for $85 million IPO
Coherus BioSciences, which is developing a biosimilar version of Amgen's Enbrel treatment for inflammatory diseases, announced terms for its IPO on Friday. The Redwood City, CA-based company plans to raise $85 million by offering 6.3 million shares at a price...read more